Evotec reports that its Seattle-based subsidiary, Just–Evotec Biologics, expanded its relationship with Advanced BioScience Laboratories (ABL), a CDMO serving the U.S. government and the biopharmaceutical industry.
The expansion is covered under a new contract funded entirely by Federal funds under an indefinite delivery/indefinite quantity contract awarded to ABL from National Institute of Allergy and Infectious Disease and the Department of Health and Human Services.
The new agreement builds on previous collaborations between Just–Evotec Biologics and ABL to design highly efficient manufacturing processes for broadly neutralizing antibodies (bNAbs) against HIV, according to Matthias Evers, PhD, CBO of Evotec. Under the expanded relationship, Just–Evotec Biologics will develop a third bNAb and perform large-scale cGMP manufacturing campaigns for both this bNAb and a previously developed bNAb against HIV for a Phase I clinical study. Just–Evotec Biologics will also provide release and stability testing services.
“By leveraging Just–Evotec Biologics’ next-generation biomanufacturing platform we provide an integrated development and manufacturing solution for our partner to support the delivery of new therapeutic options targeting HIV together,” said Evers.
“ABL has a long history of supporting the U.S. government’s mission to develop effective prevention and therapeutic products against HIV,” added Lauren Hudacik, president and CEO of ABL. “This expansion of partnership with Just–Evotec Biologics strengthens that tradition.”
